Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) were up 9.3% during mid-day trading on Friday . The stock traded as high as $17.63 and last traded at $17.62. Approximately 109,554 shares traded hands during mid-day trading, a decline of 46% from the average daily volume of 201,550 shares. The stock had previously closed at $16.12.
Analyst Ratings Changes
Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a research note on Tuesday, November 12th.
View Our Latest Stock Report on PLSE
Pulse Biosciences Price Performance
The firm has a 50 day moving average of $17.24 and a 200-day moving average of $15.25.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter last year, the company posted ($0.19) earnings per share.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in PLSE. Vanguard Group Inc. raised its position in Pulse Biosciences by 28.8% during the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company's stock valued at $7,379,000 after purchasing an additional 189,227 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company's stock valued at $2,598,000 after purchasing an additional 97,565 shares in the last quarter. State Street Corp raised its position in Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company's stock valued at $8,092,000 after purchasing an additional 69,696 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Pulse Biosciences during the third quarter worth $588,000. Finally, Geode Capital Management LLC increased its holdings in shares of Pulse Biosciences by 7.8% during the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company's stock worth $8,020,000 after buying an additional 33,200 shares in the last quarter. 76.95% of the stock is currently owned by institutional investors and hedge funds.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
